Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Han Deng

Showing results (221-230 of 235) with videos related to

Pageof 24
Sort By:
BMC Genomics|November 7, 2013
Global analysis of the differentially expressed miRNAs of prostate cancer in Chinese patientsHui-chan He, Zhao-dong Han, Qi-shan Dai, et al.
Molecular Biology Reports|January 24, 2014
MicroRNA-30c serves as an independent biochemical recurrence predictor and potential tumor suppressor for prostate cancerXiao-hui Ling, Zhao-dong Han, Dan Xia, et al.
FEBS Letters|June 20, 2012
MicroRNA-23b downregulates peroxiredoxin III in human prostate cancerHui-chan He, Jian-guo Zhu, Xi-bin Chen, et al.
Theranostics|September 15, 2020
Erratum: The WW domains dictate isoform-specific regulation of YAP1 stability and pancreatic cancer cell malignancy: ErratumQiang Guo, Meiyu Quan, Jinglai Dong, et al.
Theranostics|April 16, 2020
The WW domains dictate isoform-specific regulation of YAP1 stability and pancreatic cancer cell malignancyQiang Guo, Meiyu Quan, Jinglai Dong, et al.
BMC Cancer|June 19, 2012
SOXs in human prostate cancer: implication as progression and prognosis factorsWei-de Zhong, Guo-qiang Qin, Qi-shan Dai, et al.
Cell Reports|April 26, 2024
Precision off-the-shelf natural killer cell therapies for oncology with logic-gated gene circuitsNicholas W Frankel, Han Deng, Gozde Yucel, et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|August 3, 2016
Serum Liver Fibrosis Markers in the Prognosis of Liver Cirrhosis: A Prospective Observational StudyXingshun Qi, Xu Liu, Yongguo Zhang, et al.
Journal of Hematology & Oncology|December 29, 2022
FTL004, an anti-CD38 mAb with negligible RBC binding and enhanced pro-apoptotic activity, is a novel candidate for treatments of multiple myeloma and non-Hodgkin lymphomaGuangbing Zhang, Cuiyu Guo, Yan Wang, et al.
Developmental Cell|May 22, 2024
SMARCA5 reprograms AKR1B1-mediated fructose metabolism to control leukemogenesisPeng-Cheng Yu, Dan Hou, Binhe Chang, et al.
Pageof 24

Showing results (221-230 of 235) with videos related to

Sort By:
Pageof 24
BMC Genomics|November 7, 2013
Global analysis of the differentially expressed miRNAs of prostate cancer in Chinese patientsHui-chan He, Zhao-dong Han, Qi-shan Dai, et al.
Molecular Biology Reports|January 24, 2014
MicroRNA-30c serves as an independent biochemical recurrence predictor and potential tumor suppressor for prostate cancerXiao-hui Ling, Zhao-dong Han, Dan Xia, et al.
FEBS Letters|June 20, 2012
MicroRNA-23b downregulates peroxiredoxin III in human prostate cancerHui-chan He, Jian-guo Zhu, Xi-bin Chen, et al.
Theranostics|September 15, 2020
Erratum: The WW domains dictate isoform-specific regulation of YAP1 stability and pancreatic cancer cell malignancy: ErratumQiang Guo, Meiyu Quan, Jinglai Dong, et al.
Theranostics|April 16, 2020
The WW domains dictate isoform-specific regulation of YAP1 stability and pancreatic cancer cell malignancyQiang Guo, Meiyu Quan, Jinglai Dong, et al.
BMC Cancer|June 19, 2012
SOXs in human prostate cancer: implication as progression and prognosis factorsWei-de Zhong, Guo-qiang Qin, Qi-shan Dai, et al.
Cell Reports|April 26, 2024
Precision off-the-shelf natural killer cell therapies for oncology with logic-gated gene circuitsNicholas W Frankel, Han Deng, Gozde Yucel, et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|August 3, 2016
Serum Liver Fibrosis Markers in the Prognosis of Liver Cirrhosis: A Prospective Observational StudyXingshun Qi, Xu Liu, Yongguo Zhang, et al.
Journal of Hematology & Oncology|December 29, 2022
FTL004, an anti-CD38 mAb with negligible RBC binding and enhanced pro-apoptotic activity, is a novel candidate for treatments of multiple myeloma and non-Hodgkin lymphomaGuangbing Zhang, Cuiyu Guo, Yan Wang, et al.
Developmental Cell|May 22, 2024
SMARCA5 reprograms AKR1B1-mediated fructose metabolism to control leukemogenesisPeng-Cheng Yu, Dan Hou, Binhe Chang, et al.
Pageof 24